McKesson Competitors

GlaxoSmithKline (NYSE:GSK) and McKesson (NYSE:MCK) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Dividends

GlaxoSmithKline pays an annual dividend of $2.52 per share and has a dividend yield of 7.0%. McKesson pays an annual dividend of $1.68 per share and has a dividend yield of 0.9%. GlaxoSmithKline pays out 79.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. McKesson pays out 11.2% of its earnings in the form of a dividend. GlaxoSmithKline has raised its dividend for 1 consecutive years and McKesson has raised its dividend for 4 consecutive years.

Risk & Volatility

GlaxoSmithKline has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, McKesson has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for GlaxoSmithKline and McKesson, as provided by MarketBeat.

McKesson has a consensus target price of $196.00, suggesting a potential upside of 2.18%. Given McKesson's stronger consensus rating and higher possible upside, analysts clearly believe McKesson is more favorable than GlaxoSmithKline.

Valuation and Earnings

This table compares GlaxoSmithKline and McKesson's gross revenue, earnings per share and valuation.

GlaxoSmithKline has higher earnings, but lower revenue than McKesson. GlaxoSmithKline is trading at a lower price-to-earnings ratio than McKesson, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

11.8% of GlaxoSmithKline shares are held by institutional investors. Comparatively, 85.6% of McKesson shares are held by institutional investors. 10.0% of GlaxoSmithKline shares are held by company insiders. Comparatively, 0.3% of McKesson shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares GlaxoSmithKline and McKesson's net margins, return on equity and return on assets.

Summary

McKesson beats GlaxoSmithKline on 12 of the 18 factors compared between the two stocks.

Stryker (NYSE:SYK) and McKesson (NYSE:MCK) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends.

Analyst Recommendations

This is a summary of current recommendations for Stryker and McKesson, as reported by MarketBeat.com.

Stryker currently has a consensus price target of $234.6818, indicating a potential downside of 6.81%. McKesson has a consensus price target of $196.00, indicating a potential upside of 2.18%. Given McKesson's stronger consensus rating and higher possible upside, analysts plainly believe McKesson is more favorable than Stryker.

Valuation and Earnings

This table compares Stryker and McKesson's top-line revenue, earnings per share and valuation.

Stryker has higher earnings, but lower revenue than McKesson. McKesson is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Stryker and McKesson's net margins, return on equity and return on assets.

Dividends

Stryker pays an annual dividend of $2.52 per share and has a dividend yield of 1.0%. McKesson pays an annual dividend of $1.68 per share and has a dividend yield of 0.9%. Stryker pays out 30.5% of its earnings in the form of a dividend. McKesson pays out 11.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has increased its dividend for 1 consecutive years and McKesson has increased its dividend for 4 consecutive years.

Volatility & Risk

Stryker has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, McKesson has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.

Institutional and Insider Ownership

71.5% of Stryker shares are owned by institutional investors. Comparatively, 85.6% of McKesson shares are owned by institutional investors. 6.8% of Stryker shares are owned by company insiders. Comparatively, 0.3% of McKesson shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

McKesson beats Stryker on 9 of the 17 factors compared between the two stocks.

McKesson (NYSE:MCK) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Earnings and Valuation

This table compares McKesson and Intuitive Surgical's revenue, earnings per share (EPS) and valuation.

Intuitive Surgical has lower revenue, but higher earnings than McKesson. McKesson is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

McKesson has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.

Insider & Institutional Ownership

85.6% of McKesson shares are held by institutional investors. Comparatively, 86.5% of Intuitive Surgical shares are held by institutional investors. 0.3% of McKesson shares are held by insiders. Comparatively, 1.6% of Intuitive Surgical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for McKesson and Intuitive Surgical, as reported by MarketBeat.com.

McKesson currently has a consensus price target of $196.00, suggesting a potential upside of 2.18%. Intuitive Surgical has a consensus price target of $750.9444, suggesting a potential downside of 3.62%. Given McKesson's stronger consensus rating and higher probable upside, analysts clearly believe McKesson is more favorable than Intuitive Surgical.

Profitability

This table compares McKesson and Intuitive Surgical's net margins, return on equity and return on assets.

Summary

Intuitive Surgical beats McKesson on 9 of the 15 factors compared between the two stocks.

Anthem (NYSE:ANTM) and McKesson (NYSE:MCK) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.

Dividends

Anthem pays an annual dividend of $4.52 per share and has a dividend yield of 1.3%. McKesson pays an annual dividend of $1.68 per share and has a dividend yield of 0.9%. Anthem pays out 23.3% of its earnings in the form of a dividend. McKesson pays out 11.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Anthem has raised its dividend for 1 consecutive years and McKesson has raised its dividend for 4 consecutive years.

Risk & Volatility

Anthem has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, McKesson has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Anthem and McKesson, as provided by MarketBeat.

Anthem currently has a consensus target price of $358.85, suggesting a potential downside of 0.24%. McKesson has a consensus target price of $196.00, suggesting a potential upside of 2.18%. Given McKesson's stronger consensus rating and higher possible upside, analysts clearly believe McKesson is more favorable than Anthem.

Institutional & Insider Ownership

89.4% of Anthem shares are held by institutional investors. Comparatively, 85.6% of McKesson shares are held by institutional investors. 0.2% of Anthem shares are held by insiders. Comparatively, 0.3% of McKesson shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Anthem and McKesson's revenue, earnings per share (EPS) and valuation.

Anthem has higher earnings, but lower revenue than McKesson. McKesson is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Anthem and McKesson's net margins, return on equity and return on assets.

Summary

Anthem beats McKesson on 10 of the 18 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and McKesson (NYSE:MCK) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Risk & Volatility

Gilead Sciences has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, McKesson has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.

Profitability

This table compares Gilead Sciences and McKesson's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings for Gilead Sciences and McKesson, as provided by MarketBeat.com.

Gilead Sciences currently has a consensus price target of $97.2308, indicating a potential upside of 50.26%. McKesson has a consensus price target of $196.00, indicating a potential upside of 2.18%. Given Gilead Sciences' higher possible upside, equities analysts clearly believe Gilead Sciences is more favorable than McKesson.

Valuation and Earnings

This table compares Gilead Sciences and McKesson's gross revenue, earnings per share and valuation.

Gilead Sciences has higher earnings, but lower revenue than McKesson. Gilead Sciences is trading at a lower price-to-earnings ratio than McKesson, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

76.4% of Gilead Sciences shares are held by institutional investors. Comparatively, 85.6% of McKesson shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by insiders. Comparatively, 0.3% of McKesson shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Dividends

Gilead Sciences pays an annual dividend of $2.84 per share and has a dividend yield of 4.4%. McKesson pays an annual dividend of $1.68 per share and has a dividend yield of 0.9%. Gilead Sciences pays out 46.3% of its earnings in the form of a dividend. McKesson pays out 11.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has raised its dividend for 1 consecutive years and McKesson has raised its dividend for 4 consecutive years.

Summary

McKesson beats Gilead Sciences on 10 of the 18 factors compared between the two stocks.

Zoetis (NYSE:ZTS) and McKesson (NYSE:MCK) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Dividends

Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.6%. McKesson pays an annual dividend of $1.68 per share and has a dividend yield of 0.9%. Zoetis pays out 27.5% of its earnings in the form of a dividend. McKesson pays out 11.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 1 consecutive years and McKesson has raised its dividend for 4 consecutive years. McKesson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional & Insider Ownership

92.5% of Zoetis shares are owned by institutional investors. Comparatively, 85.6% of McKesson shares are owned by institutional investors. 0.2% of Zoetis shares are owned by insiders. Comparatively, 0.3% of McKesson shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Zoetis and McKesson, as provided by MarketBeat.com.

Zoetis currently has a consensus target price of $170.0833, suggesting a potential upside of 4.50%. McKesson has a consensus target price of $196.00, suggesting a potential upside of 2.18%. Given Zoetis' higher possible upside, analysts plainly believe Zoetis is more favorable than McKesson.

Profitability

This table compares Zoetis and McKesson's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Zoetis and McKesson's top-line revenue, earnings per share (EPS) and valuation.

Zoetis has higher earnings, but lower revenue than McKesson. McKesson is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Zoetis has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, McKesson has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.

Summary

McKesson beats Zoetis on 10 of the 18 factors compared between the two stocks.